In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival

• Published in: British journal of cancer 2012-06, Vol.106 (12), p.1967-1975
• Main Authors: Bicaku, E, Xiong, Y, Marchion, D C, Chon, H S, Stickles, X B, Chen, N, Judson, P L, Hakam, A, Gonzalez-Bosquet, J, Wenham, R M, Apte, S M, Fulp, W, Cubitt, C L, Chen, D-T, Lancaster, J M
• Format: Article
• Language: English
• Subjects: 631/67/1059/602; 631/80/86; 692/699/67/1517/1709; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carboplatin - administration & dosage; Cell Line, Tumor - immunology; Cisplatin - administration & dosage; Cyclic AMP Response Element-Binding Protein; Drug Resistance; Epidemiology; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Molecular Medicine; Oncology; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - mortality; Paclitaxel - administration & dosage; Signal Transduction; Translational Therapeutics; Treatment Outcome; Tumors
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.2012.207

Background: Carboplatin and cisplatin, alone or in combination with paclitaxel, have similar efficacies against ovarian cancer (OVCA) yet exhibit different toxicity profiles. We characterised the common and unique cellular pathways that underlie OVCA response to these drugs and analyse whether they have a role in OVCA survival. Methods: Ovarian cancer cell lines ( n =36) were treated with carboplatin, cisplatin, paclitaxel, or carboplatin–paclitaxel (CPTX). For each cell line, IC 50 levels were quantified and pre-treatment gene expression analyses were performed. Genes demonstrating expression/IC 50 correlations (measured by Pearson; P